RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...

As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare ...

The U.S. Food and Drug Administration announced seven metered-dose inhalers (MDIs) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S.

October 7, 2011 — The US Food and Drug Administration (FDA) has granted approval for an ipratropium bromide and albuterol sulfate inhalation spray (Combivent Respimat Inhalation Spray, Boehringer ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use. If you ...

U.S. regulators have stamped an approval on a new inhaler that reduces the required inhalations per dose for Boehringer Ingelheim's treatment for chronic obstructive pulmonary disease (COPD), the ...

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the US Food and Drug Administration (US FDA) has approved Combivent Respimat, a new, propellant-free inhaler product that uses a slow-moving ...

The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...

A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and respiratory ...

A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and respiratory ...